coxsackievirus
member
genu
enteroviru
famili
picornavirida
divid
two
group
basi
pathogen
mice
serotyp
coxsacki
virus
cav
serotyp
coxsacki
b
virus
cvb
cvb
implic
childhood
myocard
end
sinc
six
cvb
serotyp
shown
caus
myocard
also
wide
varieti
human
diseas
includ
common
cold
cardiomyopathi
diabet
neurolog
disord
inflamm
numer
outbreak
cvb
infect
note
commun
level
coxsacki
viru
known
caus
widespread
nationwid
epidem
unit
state
particularli
moreov
associ
sever
human
diseas
includ
enceph
myocard
immunocompromis
children
cn
diseas
older
adult
sinc
direct
viral
cytotox
one
possibl
caus
damag
target
caus
agent
limit
extent
damag
especi
earli
treatment
enterovirusspecif
vaccin
therapeut
reagent
avail
clinic
use
although
report
present
effect
candid
murin
model
great
number
picornaviru
replic
inhibitor
describ
vitro
shown
effect
vivo
none
approv
clinic
use
gancyclovir
cidofovir
studi
myocard
caus
cytomegaloviru
mice
evid
also
work
enterovirusinduc
myocard
acyclovir
success
use
treat
myocard
associ
epsteinbarr
viru
varicella
report
demonstr
acyclovir
effect
cvb
myocard
arbidol
antivir
molecul
first
develop
russia
chemic
name
dimethylamino
methyl
phenylthio
methyl
hydrochlorid
monohydr
arbidol
first
found
widespectrum
antivir
activ
human
influenza
viru
shown
inhibit
reproduct
rimantadineresist
human
influenza
viru
avian
virus
influenza
virus
b
c
mani
studi
arbidol
also
exhibit
broad
potent
antivir
activ
number
virus
includ
respiratori
syncyti
viru
adenoviru
parainfluenza
viru
type
rhinoviru
type
avian
coronaviru
infecti
bronchiti
viru
marek
diseas
viru
hepat
b
viru
hepat
c
viru
previou
studi
arbidol
show
broadspectrum
antivir
activ
number
respiratori
virus
includ
flua
rsv
hrv
vitro
extens
list
arbidolsensit
virus
includ
rna
dna
virus
envelop
nonenvelop
virus
phdepend
independ
virus
emphas
broad
spectrum
arbidol
antivir
activ
time
wide
spectrum
arbidol
activ
suggest
arbidol
target
common
critic
step
interact
studi
systemat
investig
antivir
activ
arbidol
vitro
vivo
arbidol
synthes
qianjiang
pharmaceut
co
ltd
hubei
china
compound
initi
dissolv
dimethyl
sulfoxid
dmso
dilut
complet
test
medium
final
maximum
dmso
concentr
show
effect
cell
cultur
therefor
dmso
also
ad
nocompound
control
sampl
efficaci
prepar
appear
chang
upon
freez
shortterm
storag
month
vivo
experi
compound
dissolv
methylcellulos
solut
human
laryng
carcinoma
cell
maintain
laboratori
routin
grown
eagl
minim
essenti
medium
plu
nonessenti
amino
acid
eagl
mem
sigma
supplement
fetal
bovin
serum
lglutamin
uml
penicillin
mgml
streptomycin
test
medium
use
cytotox
assay
well
antivir
assay
contain
appropri
serum
maintain
laboratori
propag
cell
viru
store
small
aliquot
use
viru
titrat
perform
limit
dilut
method
use
plate
six
well
per
dilut
viru
titer
estim
cytopathogen
cell
induc
viral
infect
express
tissu
cultur
infecti
dosesml
cytotox
antivir
activ
compound
determin
quantit
colorimetr
mtt
tetrazolium
bromid
assay
briefli
cell
seed
cell
per
well
plate
grown
subconflu
remov
growth
medium
serial
twofold
dilut
compound
test
medium
ad
dilut
four
well
infect
ml
viru
four
well
left
uninfect
toxic
determin
dose
arbidol
ad
plate
daili
sinc
halflif
cultur
cell
h
plate
incub
develop
cytopath
effect
cpe
monitor
daili
light
microscopi
virusinfect
untreat
cell
show
cpe
time
point
cultur
medium
remov
mtt
solut
mgml
phosphatebuff
salin
pb
ad
well
plate
incub
h
allow
mtt
formazan
format
remov
supernat
dmso
ad
solubil
formazan
crystal
homogen
micropl
shaker
min
optic
densiti
od
read
use
micropl
spectrophotomet
doubl
wavelength
nm
result
express
percentag
od
valu
treat
cell
cultur
respect
untreat
one
data
analyz
spss
cytotox
inhibitori
concentr
agent
determin
thu
therapeut
index
ti
compound
also
determin
dilut
test
triplic
set
experi
three
control
well
without
drug
includ
serial
twofold
dilut
compound
dissolv
mem
incub
cell
microtit
plate
h
atmospher
remov
compound
cell
wash
twice
pb
challeng
ml
incub
cell
wash
twice
pb
incub
test
medium
typic
cpe
visibl
inhibit
virusinduc
cpe
score
light
microscopi
measur
mtt
assay
four
untreat
viru
control
four
uninfect
untreat
cell
control
includ
assay
data
present
result
experi
perform
triplic
viral
suspens
cocultur
serial
twofold
dilut
compound
h
ad
confluent
cell
incub
solut
contain
compound
virus
remov
cell
rins
care
pb
incub
test
medium
assay
perform
follow
protocol
describ
experi
carri
follow
differ
confluent
cell
monolay
infect
ml
virus
h
cell
sheet
wash
pb
overlaid
differ
dose
compound
test
medium
rna
extract
supernat
cell
compound
treatment
viru
infect
use
trizol
reagent
invitrogen
also
purifi
rna
uninfect
cell
infect
cell
without
treatment
test
medium
neg
posit
blank
control
rna
dissolv
rnasefre
water
concentr
measur
use
spectrophotomet
biorad
sampl
adjust
accord
method
yamamoto
et
al
revers
transcript
carri
min
min
random
primer
use
prepar
complementari
dna
templat
pcr
forward
revers
primer
use
rtpcr
respect
use
intern
control
sequenc
twentyeight
cycl
pcr
carri
reaction
mixtur
contain
synthes
cdna
pcr
buffer
dntp
primer
primer
taq
dna
polymeras
miner
oil
place
top
pcr
mixtur
prevent
evapor
program
thermal
cycler
set
follow
min
pcr
product
load
onto
agaros
gel
contain
ethidium
bromid
separ
electrophoresi
gel
scan
use
photoanalysi
system
analyz
use
four
star
bioimag
softwar
calcul
ratio
peak
valu
adsorpt
cvb
specificpathogenfre
male
balbc
mice
week
old
g
obtain
anim
center
wuhan
univers
use
experi
sixtyfour
balbc
mice
micegroup
four
group
use
experi
fortyeight
mice
infect
intraperiton
ml
remain
use
normal
control
inject
intraperiton
volum
pb
infect
hour
mice
treat
oral
gavag
po
ml
arbidol
correspond
approxim
mgkg
bodi
weightday
treatment
continu
daili
day
unless
otherwis
indic
viru
control
group
normal
pb
control
group
receiv
methylcellulos
solut
instead
compound
eight
mice
group
sacrif
cervic
disloc
day
viral
exposur
bodi
weight
mice
record
daili
anim
kill
lung
heart
harvest
weigh
organ
four
mice
group
subsequ
homogen
weightvolum
suspens
test
medium
homogen
frozen
thaw
twice
releas
viru
centrifug
rpm
min
viru
titrat
determin
plaqu
assay
organ
anoth
four
mice
use
patholog
examin
stain
lung
index
express
ratio
mean
lung
weight
mean
bodi
weight
remain
eight
anim
group
observ
daili
chang
bodi
weight
death
titer
infecti
viru
particl
determin
standard
plaqu
format
assay
replic
aliquot
serial
dilut
inocul
onto
cell
monolay
plate
incub
two
day
later
cpe
read
result
express
pfu
arbidol
show
signific
inhibitori
activ
ad
infect
ti
mild
inhibitori
activ
cvb
ad
infect
close
compound
ti
see
tabl
investig
direct
inactiv
effect
arbidol
viru
treat
h
concentr
arbidol
rang
shown
tabl
arbidol
virucid
inhibit
cpe
cell
ti
rna
extract
supernat
cell
well
plate
treat
compound
viru
infect
use
trizol
invitrogen
accord
manufactur
protocol
specif
amplifi
product
bp
bp
two
pair
primer
identifi
describ
materi
method
figur
gel
pictur
pcr
product
gel
scan
use
photoanalysi
system
analyz
use
four
star
bioimag
softwar
ratio
peak
valu
adsorpt
cvb
calcul
softwar
shown
fig
quantit
relationship
ratio
dose
arbidol
ratio
decreas
increas
dose
arbidol
suggest
synthesi
rna
decreas
increas
dose
compound
treatment
done
infect
viral
control
group
anim
show
tendenc
huddl
diminish
vital
ruffl
fur
weight
loss
fig
observ
day
infect
day
group
anim
began
die
day
die
fig
compoundtr
group
anim
receiv
mgkg
bodi
weightday
began
show
behavior
chang
lose
weight
day
fig
began
die
day
challeng
day
half
surviv
fig
anim
receiv
mgkg
bodi
weightday
normal
control
anim
show
abnorm
period
except
former
group
slight
weight
loss
fig
ip
infect
led
increas
mean
lung
weight
decreas
mean
bodi
weight
day
viru
exposur
lung
index
bodi
weightday
group
significantli
lower
viral
control
group
group
almost
normal
group
signific
differ
normal
group
lung
index
fig
signific
differ
among
group
anim
mean
heart
weight
data
shown
four
anim
group
sacrif
day
viral
exposur
tissu
sampl
obtain
lung
kidney
liver
heart
spleen
patholog
examin
shown
microscop
lung
viral
control
anim
thicken
alveoli
wall
due
edema
alveolar
epithelia
prolifer
interstiti
cell
interstiti
lymphocyt
macrophag
inflammatori
infiltr
hemorrhag
fig
heart
viral
control
anim
denatur
cardiac
muscl
cell
fig
tissu
sampl
remain
anim
chang
except
lung
anim
receiv
mgkg
bodi
weightday
show
local
hemorrhag
data
shown
four
anim
group
sacrif
day
viral
exposur
tissu
sampl
obtain
lung
heart
virolog
examin
viru
titer
lung
heart
significantli
lower
mice
receiv
oral
administr
arbidol
daili
day
viral
control
group
group
treat
arbidol
mgkg
bodi
weightday
mean
viru
yield
lung
around
viral
plaqueslung
respect
wherea
yield
viru
control
mice
viral
plaqueslung
fig
mean
viru
yield
heart
reduc
viral
plaquesheart
respect
wherea
yield
viruscontrol
mice
viral
plaquesheart
fig
arbidol
russianmad
broadspectrum
antivir
compound
shown
inhibit
fusion
influenza
b
virus
within
endosom
influenzavirusinduc
fusion
need
acid
environ
ph
slight
increas
ph
abolish
fusion
process
sinc
arbidol
weak
base
may
elev
endosom
ph
abrog
virusendosom
fusion
arbidol
also
shown
exert
antivir
activ
phdepend
virus
hepat
b
viru
rhinoviru
moreov
arbidol
demonstr
low
toxic
upon
singledos
oral
administr
mani
anim
model
anim
lethal
dose
mgkg
mice
mgkg
rat
mgkg
guinea
pig
longterm
arbidol
intak
studi
also
show
patholog
chang
anim
confirm
clinic
hematolog
biochem
patholog
data
therapeut
dose
arbidol
possess
mutagen
teratogen
activ
studi
test
antivir
activ
arbidol
vitro
vivo
like
enterovirus
cvb
small
rna
viru
replic
lack
lipid
envelop
stabl
acid
ph
primarili
cultur
cell
infect
treat
arbidol
differ
method
arbidol
found
present
potent
antivir
activ
ad
infect
virucid
assay
arbidol
exhibit
strong
effect
inhibit
cpe
cell
ti
higher
treatment
data
suggest
arbidol
strong
antivir
effect
adsorpt
step
also
cocultur
cell
differ
dose
arbidol
infect
studi
whether
still
antivir
effect
viru
entri
host
cell
mtt
assay
show
arbidol
inhibitori
activ
ti
see
tabl
semiquantit
rtpcr
data
suggest
arbidol
prevent
synthesi
rna
dosedepend
manner
short
data
demonstr
arbidol
induc
durabl
antivir
activ
host
cell
block
adsorpt
viral
particl
onto
cell
also
inhibit
late
stage
viral
replic
cycl
studi
whether
arbidol
antivir
abil
vivo
establish
mous
model
infect
mice
infect
symptom
circulatori
failur
cyanosi
lack
blood
perfus
tail
auricl
evid
viru
replic
heart
lung
patholog
find
consist
result
viru
isol
viral
control
mice
die
day
infect
thu
infect
balbc
mice
suitabl
vivo
model
studi
vivo
antivir
activ
oral
administ
arbidol
mgkg
bodi
weightday
day
infect
coxsackieviru
day
significantli
enhanc
surviv
rate
reduc
viru
yield
releas
patholog
abnorm
lung
heart
summari
result
suggest
arbidol
elicit
protect
antivir
activ
vitro
vivo
exact
antivir
mechan
arbidol
still
unknown
arbidol
may
play
signific
role
medic
countermeasur
infect
